Logo

CLYM

Climb Bio, Inc.

CLYM

Climb Bio, Inc. • NASDAQ
$1.89 ▲ 2.72% (+0.05)
Market Cap $128.87 M
52w High $3.30
52w Low $1.05
Dividend Yield 0%
P/E -3.2
Volume 123.35K
Outstanding Shares 68.18M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $14.892M ▲ $-12.888M ▼ 0% $-0.19 ▼ $-12.859M ▼
Q2-2025 $0 $10.639M ▼ $-8.666M ▲ 0% $-0.13 ▲ $-8.628M ▲
Q1-2025 $0 $23.018M ▲ $-20.781M ▼ 0% $-0.31 ▼ $-23.018M ▼
Q4-2024 $0 $10.911M ▼ $-8.416M ▲ 0% $-0.13 $-10.911M ▲
Q3-2024 $0 $11.732M $-8.895M 0% $-0.13 $-11.732M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $86.901M ▲ $182.304M ▼ $5.301M ▼ $177.003M ▼
Q2-2025 $84.703M ▼ $192.386M ▼ $6.622M ▼ $185.764M ▼
Q1-2025 $98.062M ▼ $200.74M ▼ $7.355M ▲ $193.385M ▼
Q4-2024 $150.919M ▼ $217.187M ▼ $5.306M ▲ $211.881M ▼
Q3-2024 $193.351M $222.199M $3.423M $218.776M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-12.888M ▼ $-12.139M ▼ $15.26M ▲ $0 $3.121M ▲ $-12.248M ▼
Q2-2025 $-8.666M ▲ $-11.148M ▲ $4.786M ▲ $0 $-6.338M ▲ $-11.225M ▲
Q1-2025 $-20.781M ▼ $-15.434M ▼ $-42.751M ▲ $0 ▼ $-58.209M ▲ $-15.434M ▼
Q4-2024 $-8.416M ▲ $-5.521M ▲ $-53.409M ▲ $41K ▼ $-58.946M ▲ $-5.521M ▲
Q3-2024 $-8.895M $-7.555M $-71.789M $2.271M $-76.965M $-7.555M

Five-Year Company Overview

Income Statement

Income Statement Climb Bio is still a pure research‑stage company with no product sales yet, so all activity flows through expenses rather than revenue. The income statement shows a consistent pattern of research and operating costs leading to modest but ongoing losses each year. Those losses have been relatively steady rather than exploding, which suggests controlled spending, but the business is clearly in “investing mode” rather than anywhere near profitability. Earnings per share remain negative, which is typical for an early‑stage biotech that is funding trials and platform development long before any potential approvals or royalties arrive.

Balance Sheet

Balance Sheet The balance sheet is small and simple, reflecting a young, focused biotech. Assets have grown from a very low base, with cash making up the bulk of what the company owns. There is essentially no financial debt, so the company is funded mainly by shareholder equity rather than borrowing. Equity is positive, which means past funding rounds have more than covered accumulated losses so far. At the same time, the absolute size of the asset base is limited, so the financial cushion is not large and continued progress will depend on careful cash management and access to fresh capital over time.

Cash Flow

Cash Flow Cash flows show a classic early‑stage biotech profile: money steadily flowing out to fund operations, with no offsetting inflows from products. Operating cash burn has been consistent and not extreme, suggesting a relatively lean cost structure. There is virtually no spending on large physical assets, which fits a science‑driven model built around labs, people, and external trial costs rather than heavy equipment. Free cash flow is negative but predictable, so the main questions are how long current resources last and when the company chooses to raise additional funds, especially as it moves into more expensive later‑stage trials.

Competitive Edge

Competitive Edge Climb Bio’s competitive position rests on differentiated antibody science in a crowded but high‑value area: immune‑mediated and kidney diseases. Budoprutug targets B‑cells through CD19 with the flexibility of both intravenous and convenient under‑the‑skin dosing, which could be attractive in chronic autoimmune care. CLYM116 brings a novel “sweeper” mechanism against APRIL, aiming for deeper and longer‑lasting effects than first‑generation drugs in IgA nephropathy. Together, these programs give the company a clear scientific story and potential product advantages. On the other hand, the targets themselves are well known, and larger players are active in both the CD19 and APRIL spaces, so Climb Bio’s edge will depend on how convincingly its data show better efficacy, durability, safety, or convenience versus competitors.

Innovation and R&D

Innovation and R&D Innovation is where Climb Bio is strongest. It is concentrating R&D on two lead antibodies: budoprutug, an enhanced B‑cell depletor with a patient‑friendly subcutaneous form, and CLYM116, an anti‑APRIL antibody designed to repeatedly bind and clear its target through a pH‑dependent recycling mechanism. Early clinical signals for budoprutug and strong preclinical data for CLYM116 support the idea that these are not “me too” drugs but potentially more potent or convenient options. The R&D strategy is to apply these technologies across several autoimmune and kidney diseases, which spreads scientific bets without diluting focus too much. The main innovation risk is concentration: much of the company’s future hinges on just a couple of assets, so any setbacks in safety, efficacy, or dosing could have an outsized impact.

Summary

Climb Bio is a small, clinical‑stage biotech with no revenue yet, steady research‑driven losses, and a clean balance sheet with no debt and a modest but meaningful cash base. Financially, it is in the typical position of an early biotech: dependent on outside capital and on the success of its trials, with limited room for major surprises in spending. Strategically, its value is almost entirely tied to the promise of its antibody platform—particularly budoprutug and CLYM116—which aim to improve outcomes and convenience in autoimmune and kidney diseases through enhanced mechanisms and under‑the‑skin dosing. The upside case is built around strong future trial data and successful differentiation from rival therapies, while the main risks lie in clinical results, regulatory paths, competitive pressure from larger players, and the need to secure future funding as development progresses.

NEWS

November 25, 2025 · 7:00 AM UTC

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 6, 2025 · 7:01 AM UTC

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Read more

November 3, 2025 · 7:00 AM UTC

Climb Bio to Present at Upcoming Investor Conferences

Read more

October 21, 2025 · 7:00 AM UTC

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Read more

October 17, 2025 · 7:00 AM UTC

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Read more